Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

Blood (2024) 144 (21): 2237–2247.

https://doi.org/10.1182/blood.2024024493

Published: 2024

Includes: Supplemental data

Journal Articles

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Blood (2024) 144 (Supplement 1): 310.

https://doi.org/10.1182/blood-2024-193946

Published: 2024

Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Blood (2024) 144 (Supplement 1): 211.

https://doi.org/10.1182/blood-2024-194384

Published: 2024

Journal Articles

Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

Blood (2024) 144 (Supplement 1): 3108.

https://doi.org/10.1182/blood-2024-200077

Published: 2024

Journal Articles

When InO says no: understanding escape

Judith M. Boer, C. Michel Zwaan

Blood (2024) 144 (1): 2–4.

https://doi.org/10.1182/blood.2024024713

Published: 2024

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Blood (2023) 142 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2023-192042

Published: 2023

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood (2023) 142 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2023-173162

Published: 2023

Journal Articles

Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3 -ITD/ NPM1 wt Patients - a Study By the NOPHO-DB-SHIP Consortium

Blood (2023) 142 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2023-181792

Published: 2023

Journal Articles

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Amelie Polutta, Dirk Reinhardt, Andre Baruchel, Henrik Hasle, Franco Locatelli, C. Michel Zwaan, Michael Frühwald, Silke Westphal, Michael Dworzak, Heidrun Boztug, Gabriele Escherich, Thomas Lehrnbecher, Bianca F. Goemans, Brigitte Strahm, Markus Schneider, Lina Hoffmeister, Katharina Waack

Blood (2023) 142 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2023-180820

Published: 2023

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2023-189762

Published: 2023

Journal Articles

Transcriptional Heterogeneity and Clonal Evolution between Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia

Cristoforo Grasso, Peter Brazda, Brigit M. te Pas, Gitanjali Dharmadhikari, Joost B. Koedijk, Bianca F. Goemans, Olaf Heidenreich, Mirjam E. Belderbos, C. Michel Zwaan, Hendrik G. Stunnenberg, Wout Megchelenbrink

Blood (2023) 142 (Supplement 1): 2746.

https://doi.org/10.1182/blood-2023-182852

Published: 2023

Journal Articles

Europeanpediatric Acute Leukemia (EuPAL) Registry

Katarzyna Majstrowicz, Katharina Waack, Evangelia Antoniou, Naghmeh Niktoreh, Gwen Nichols, Laura Di Laurenzio, Michele S. Redell, Todd Cooper, E. Anders Kolb, Sarah K. Tasian, Franco Locatelli, C. Michel Zwaan, Dirk Reinhardt

Blood (2023) 142 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2023-189684

Published: 2023

Journal Articles

ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Sae Ishimaru, Gwenaëlle Gueguen, Seth E. Karol, Francisco J. Bautista Sirvent, Valeria Ceolin, Bianca F. Goemans, Marlous Bakker, Laura Di Laurenzio, Jennifer Lukin, Harm Van Tinteren, Gauri B. Sunkersett, Maika Onishi, Kristina Unnebrink, Dirk Reinhardt, Gwen L Nichols, E. Anders Kolb, C. Michel Zwaan

Blood (2022) 140 (Supplement 1): 3369–3370.

https://doi.org/10.1182/blood-2022-168818

Published: 2022

Journal Articles

Hydrocortisone or Placebo to Reduce Dexamethasone-Induced Neurobehavioral Side Effects: Results of a Phase 3 National, Double-Blind, Placebo-Controlled Randomized Trial with Crossover Design

Annelienke M. van Hulst, Erica L.T. van den Akker, Emma J. Verwaaijen, Marta Fiocco, Niki Rensen, Raphaële R.L. van Litsenburg, Saskia M.F. Pluijm, C. Michel Zwaan, Hanneke M. Van Santen, Rob Pieters, Andrea W.M. Evers, Martha A. Grootenhuis, Marry M. van den Heuvel-Eibrink

Blood (2022) 140 (Supplement 1): 3162–3163.

https://doi.org/10.1182/blood-2022-163329

Published: 2022

Journal Articles

Retrospective Lineage Tracing of Pediatric Acute Myeloid Leukemia Using Single-Cell Whole Genome Sequencing

Eline J.M. Bertrums, Sjors Middelkamp, Inge M. van der Werf, Freek Manders, Arianne M. Brandsma, Niels M. Groenen, Mark Verheul, Markus J. van Roosmalen, C. Michel Zwaan, Marry M. van den Heuvel-Eibrink, Bianca F. Goemans, Ruben Van Boxtel

Blood (2022) 140 (Supplement 1): 8725–8726.

https://doi.org/10.1182/blood-2022-166051

Published: 2022

Journal Articles

Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype

Henrik Hasle, Ronald M. Kline, Eigil Kjeldsen, Nik F. Nik-Abdul-Rashid, Deepa Bhojwani, Jeffrey M. Verboon, Stephanie P. DiTroia, Katherine R. Chao, Klas Raaschou-Jensen, Josefine Palle, C. Michel Zwaan, Charlotte Guldborg Nyvold, Vijay G. Sankaran, Alan B. Cantor

Blood (2022) 139 (21): 3159–3165.

https://doi.org/10.1182/blood.2021011463

Published: 2022

Includes: Supplemental data

Journal Articles

Mutational Consequences of Chemotherapy in Hematopoietic Stem and Progenitor Cells of Pediatric Cancer Patients

Eline J.M. Bertrums, Axel Rosendahl-Huber, Jurrian de Kanter, Anais C.N. van Leeuwen, Flavia Peci, C. Michel Zwaan, Bianca F. Goemans, Ruben Van Boxtel

Blood (2021) 138 (Supplement 1): 2154.

https://doi.org/10.1182/blood-2021-148471

Published: 2021

Journal Articles

Non-Infectious Morbidity during Pediatric Acute Myeloid Leukemia Chemotherapy in the Netherlands: A 15-Year Overview

Emily R. Schwartz, Kim Klein, Valerie De Haas, Natasja Dors, Marry M. van den Heuvel-Eibrink, Rutger R.G. Knops, Wim J.E. Tissing, Birgitta Versluijs, C. Michel Zwaan, Raphaele R.L. van Litsenburg, Gertjan J.L. Kaspers

Blood (2021) 138 (Supplement 1): 2293.

https://doi.org/10.1182/blood-2021-149851

Published: 2021

Journal Articles

Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis

Blood (2021) 138 (Supplement 1): 516.

https://doi.org/10.1182/blood-2021-150272

Published: 2021

NARROW

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

When InO says no: understanding escape

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3 -ITD/ NPM1 wt Patients - a Study By the NOPHO-DB-SHIP Consortium

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Transcriptional Heterogeneity and Clonal Evolution between Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia

Europeanpediatric Acute Leukemia (EuPAL) Registry

ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Hydrocortisone or Placebo to Reduce Dexamethasone-Induced Neurobehavioral Side Effects: Results of a Phase 3 National, Double-Blind, Placebo-Controlled Randomized Trial with Crossover Design

Retrospective Lineage Tracing of Pediatric Acute Myeloid Leukemia Using Single-Cell Whole Genome Sequencing

Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype

Mutational Consequences of Chemotherapy in Hematopoietic Stem and Progenitor Cells of Pediatric Cancer Patients

Non-Infectious Morbidity during Pediatric Acute Myeloid Leukemia Chemotherapy in the Netherlands: A 15-Year Overview

Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only